Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi Biologics Pays $183 Million to Acquire Bayer German Manufacturing Facility

publication date: Dec 22, 2020

WuXi Biologics of Shanghai will add more CDMO capacity by spending $183 million to acquire a Bayer facility in Germany. The German facility will be the 16th manufacturing facility for the company. The 30,000-square-meter facility will include three 1,000-liter perfusion reactors and six 2,000-liter fed-batch reactors. WuXi Bio and Bayer also announced a long-term sublease agreement and transition service contract to manufacture Bayer's Kovaltry, a Hemophilia A therapy, in the facility. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021